Conference Coverage

VIDEO: HbA1c focus of diabetes education program


 

AT AACE 2014

LAS VEGAS – In its fourth year, the Blood Sugar Basics program, which is the American College of Endocrinology and Merck’s diabetes education program, is turning its attention to hemoglobin A1c, because many patients with diabetes fail to achieve an HbA1c of 6.5% or less, the program’s leaders said.

This year’s campaign was unveiled at the annual meeting of the American Association of Clinical Endocrinologists.

With the goal of increasing the number of patients who achieve their HbA1c goal, the program has established three missions for patients: Talk to your physician; set goals and commit to a plan; and revisit and reassess.

The program’s website (bloodsugarbasics.com), which has had a facelift, provides forms and easy-to-follow guidelines for patients. The association is also distributing printed information about the program to AACE members, and this year, it is reaching out to primary care physicians, because there simply aren’t enough endocrinologists, said Dr. Etie Moghissi, who has helped develop the program since its inception in 2010.

Blood Sugar Basics is among a handful of credible diabetes education programs online, including the National Diabetes Education Program.

In a video interview, Dr. Moghissi of the department of medicine at the University of California, Los Angeles, explains the program’s goals, and why physicians should consider it as an educational source for their patients.

nmiller@frontlinemedcom.com

On Twitter @naseemsmiller

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Asymptomatic stenosis could cause cognitive impairment
MDedge Endocrinology
Better blood pressure, glycemic control in patients with type 2 diabetes on CPAP for apnea
MDedge Endocrinology
LDL particle number advantageous in managing cardiovascular risk
MDedge Endocrinology
High animal protein intake linked to later diabetes
MDedge Endocrinology
Adding empagliflozin to metformin improved glycemic control in type 2 diabetes
MDedge Endocrinology
RM-131 makes headway against diabetic gastroparesis
MDedge Endocrinology
Walking disability raises red flag in diabetics with OA
MDedge Endocrinology
Empagliflozin improves glycemia, blood pressure in type 2 diabetes study
MDedge Endocrinology
20-study analysis finds no MACE increase with saxagliptin
MDedge Endocrinology
Canagliflozin effects include weight loss in phase III placebo-controlled trial
MDedge Endocrinology